EGFR and non-small cell lung carcinoma: EGFR mutant NSCLC is not typically sensitive to immunotherapy; however, it has been suggested that the use of EGFR inhibitors can up-regulate the expression of PD-L1 through interferon-dependent pathways, enabling these tumors to benefit from immunotherapy (82).